Among CRC patients with high microbial SphK2 activity, combination therapy induced a significant expansion of effector memory CD8+ T cells within the tumor microenvironment, accompanied by a relative reduction in Tex cell subsets. The gene discussed is SPHK2; the disease is neoplasm.